Stockreport

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte, Inc.  (PCVX) 
PDF -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Cand [Read more]